Skip to main content
SpringerLink
Log in

The Author’s Reply

  • Correspondence
  • Published:
Drug Safety Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Langsjoen PH, Langsjoen JO, Langsjoen AM, et al. Treatment of statin adverse effects with supplemental Coenzyme Q10 and statin drug discontinuation. Biofactors 2005; 25(1–4): 147–52

    Article  PubMed  CAS  Google Scholar 

  2. Marcoff L, Thompson PD. The role of coenzyme Q10 in statinassociated myopathy: a systematic review. J Am Coll Cardiol 2007; 49(23): 2231–7

    Article  PubMed  CAS  Google Scholar 

  3. Thomas JE, Lee N, Thompson PD. Statins provoking MELAS syndrome: a case report. Eur Neurol 2007; 57(4): 232–5

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The author has no conflicts of interest that are directly relevant to the content of this letter.

Author information

Authors and Affiliations

  1. The WHO Foundation Collaborating Centre for International Drug Monitoring, The Uppsala Monitoring Centre, Uppsala, Sweden

    I. Ralph Edwards

Authors
  1. I. Ralph Edwards
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Edwards, I.R. The Author’s Reply. Drug-Safety 31, 182–183 (2008). https://doi.org/10.2165/00002018-200831020-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200831020-00008

Keywords

Search

Navigation